First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

3096 Background: AZD8055 is a dual mTORC1/mTORC2 inhibitor with properties that prevent the feedback activation of AKT seen with rapalogues. This is the first-in-man study of AZD8055 to determine t...